Estimating the overall survival benefit of adjuvant chemo-endocrine therapy in women over age 50 with pT1-2N0 early stage breast cancer and 21-gene recurrence score ≥26: A National Cancer Database analysis.
ER +
adjuvant chemotherapy
adjuvant endocrine therapy
breast cancer
overall survival
recurrence score
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
02
09
2023
received:
29
01
2023
accepted:
12
09
2023
medline:
23
10
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
ppublish
Résumé
Validation studies of the 21-gene recurrence score (RS) previously demonstrated that adjuvant chemotherapy plus endocrine therapy (CET) was associated with a significant survival benefit in women with node negative breast cancer (BC) and RS >31. However, the TAILORx trial, did not quantify the benefit of adjuvant CET in older women with node negative hormone receptor positive (HR+) BC with RS ≥26. We hypothesized that CET would be associated with improved overall survival (OS) compared to endocrine therapy (ET) in women >50 with HR+/HER2-node negative BC and RS ≥26. The National Cancer Database (NCDB) was queried to identify women >50 with RS ≥26 ER+/HER2-BC pT1-2N0M0. Chi-square and logistic regression analysis determined the difference between ET and CET. OS was analyzed using a multivariable Cox model. We included 16,745 women-4740 (28.3%) received ET and 12,005 (71.7%) received CET. Women who received CET had: moderately (OR = 1.853, p < 0.001) or poorly/undifferentiated tumors (OR = 3.875, p < 0.001), pT2 (OR = 1.356, p < 0.001), or lymph-vascular invasion (OR = 1.206, p = 0.001). After accounting for demographic and oncologic factors, 5-year OS rates were significantly superior in women receiving CET vs. ET alone (95.4% vs. 92.0%, Hazard Ratio = 0.680, p < 0.001). We observed that CET was associated with a clinically and statistically significant higher OS compared to ET alone in women >50 years of age with RS ≥26 pT1 and pT2 N0M0 HR+/HER2-breast cancer, and which suggests that cytotoxic chemotherapy has an impact on reducing mortality that is independent of induction of premature ovarian failure.
Sections du résumé
BACKGROUND
Validation studies of the 21-gene recurrence score (RS) previously demonstrated that adjuvant chemotherapy plus endocrine therapy (CET) was associated with a significant survival benefit in women with node negative breast cancer (BC) and RS >31. However, the TAILORx trial, did not quantify the benefit of adjuvant CET in older women with node negative hormone receptor positive (HR+) BC with RS ≥26. We hypothesized that CET would be associated with improved overall survival (OS) compared to endocrine therapy (ET) in women >50 with HR+/HER2-node negative BC and RS ≥26.
METHODS
The National Cancer Database (NCDB) was queried to identify women >50 with RS ≥26 ER+/HER2-BC pT1-2N0M0. Chi-square and logistic regression analysis determined the difference between ET and CET. OS was analyzed using a multivariable Cox model.
RESULTS
We included 16,745 women-4740 (28.3%) received ET and 12,005 (71.7%) received CET. Women who received CET had: moderately (OR = 1.853, p < 0.001) or poorly/undifferentiated tumors (OR = 3.875, p < 0.001), pT2 (OR = 1.356, p < 0.001), or lymph-vascular invasion (OR = 1.206, p = 0.001). After accounting for demographic and oncologic factors, 5-year OS rates were significantly superior in women receiving CET vs. ET alone (95.4% vs. 92.0%, Hazard Ratio = 0.680, p < 0.001).
CONCLUSIONS
We observed that CET was associated with a clinically and statistically significant higher OS compared to ET alone in women >50 years of age with RS ≥26 pT1 and pT2 N0M0 HR+/HER2-breast cancer, and which suggests that cytotoxic chemotherapy has an impact on reducing mortality that is independent of induction of premature ovarian failure.
Identifiants
pubmed: 37766666
doi: 10.1002/cam4.6584
pmc: PMC10587951
doi:
Substances chimiques
Receptors, Estrogen
0
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19607-19616Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Nat Rev Clin Oncol. 2022 Dec;19(12):763-774
pubmed: 36253451
Cancer Med. 2023 Oct;12(19):19607-19616
pubmed: 37766666
N Engl J Med. 2018 Jul 12;379(2):111-121
pubmed: 29860917
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Am Soc Clin Oncol Educ Book. 2015;:48-55
pubmed: 25993142
BMC Med. 2015 Aug 17;13:195
pubmed: 26278220
Eur J Cancer. 2017 Jun;78:37-44
pubmed: 28412587
Lancet. 2023 Apr 15;401(10384):1277-1292
pubmed: 37061269
J Natl Cancer Inst. 1997 Nov 19;89(22):1673-82
pubmed: 9390536
Nat Rev Dis Primers. 2019 Sep 23;5(1):66
pubmed: 31548545
Front Oncol. 2023 Apr 24;13:1115208
pubmed: 37168373
Lancet. 2012 Feb 4;379(9814):432-44
pubmed: 22152853
Lancet Oncol. 2021 Apr;22(4):476-488
pubmed: 33721561
N Engl J Med. 2021 Dec 16;385(25):2336-2347
pubmed: 34914339
J Clin Oncol. 2006 Aug 10;24(23):3726-34
pubmed: 16720680
Cancers (Basel). 2022 May 23;14(10):
pubmed: 35626173
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
N Engl J Med. 2016 Aug 25;375(8):717-29
pubmed: 27557300
Eur J Cancer. 2003 Aug;39(12):1711-7
pubmed: 12888366
Breast Cancer Res. 2010;12(1):R1
pubmed: 20053270
J Clin Oncol. 2006 Dec 20;24(36):5769-79
pubmed: 17130515
JAMA Oncol. 2020 Mar 1;6(3):367-374
pubmed: 31566680